Continuum Advisory’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
TWC
ACH
DCM
Continuum Advisory's ABCL Position: Q2 2026 in Review
Continuum Advisory opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 93 shares worth $730. The stake represents ﹤0.01% of the portfolio and ranks #1886 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in ABCL as recently as Q1 2025.
Continuum Advisory first reported a position in ABCL in Q1 2024 and has held it in 6 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.
- Continuum Advisory held 93 shares of AbCellera Biologics worth $730 as of Q2 2026.
- AbCellera Biologics was a new Continuum Advisory position in Q2 2026.
- AbCellera Biologics made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1886 holding.
- Continuum Advisory first reported a position in AbCellera Biologics in Q1 2024 and has held it in 6 quarters since.
- 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.
Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.